Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: In vitro studies

British Journal of Pharmacology

Volumn 135, Issue 2, 2002, Pages 333-343

  Stasch, Johannes Peter ^a   Alonso Alija, Cristina ^a   Apeler, Heiner ^a   Dembowsky, Klaus ^a   Feurer, Achim ^a   Minuth, Torsten ^a   Perzborn, Elisabeth ^a   Schramm, Matthias ^a   Straub, Alexander ^a  

^a BAYER AG   (Germany)

Author keywords

BAY 41 8543; Cyclic GMP; Endothelial cells; Nitric oxide; ODQ; Platelets; Soluble guanylyl cyclase; Vasorelaxation; VASP; YC 1

Indexed keywords

2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; GUANYLATE CYCLASE ACTIVATOR; NITRATE; NITRIC OXIDE; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CORONARY ARTERY BLOOD FLOW; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVATION; FEMALE; HEART LEFT VENTRICLE PRESSURE; HEART RATE; HUMAN; HUMAN CELL; MALE; NONHUMAN; PERFUSION PRESSURE; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION; VASODILATATION;

ANIMALS; AORTA; CORONARY VESSELS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATORS; FEMALE; FEMORAL VEIN; GUANYLATE CYCLASE; HEART; HUMANS; MALE; MORPHOLINES; NITRIC OXIDE; PYRAZOLES; PYRIDINES; PYRIMIDINES; RABBITS; RATS; RATS, WISTAR; SWINE; VASODILATION;

EID: 0036177297     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704484     Document Type: Article

References (41)

1. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function
2. The vasodilator-stimulated phosphoprotein (VASP): Mediator of YC-1 and nitric oxide effects in human and rat platelets
3. Generation and characterization of a stable soluble guanylate cyclase overexpressing CHO cell line
4. The aggregation of blood platelets
5. Tolerance to organic nitrates: Evidence, mechanisms, clinical relevance, and strategies for prevention
6. The soluble guanylyl cyclase inhibitor 1H[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation
7. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets
8. Sensitizing soluble guanylate cyclase to become a highly CO-sensitive enzyme
9. Endothelium-derived relaxing factor: Discovery, early studies, and identification as nitric oxide (Nobel lecture)
10. Effects of the soluble guanylate cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity
11. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
12. Stoichometric and reversible phosphorylation of a 46-kDa protein in in human platelets in response to cGMP- and cAMP-elevating vasodilators
13. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein (VASP)-knock-out mice
14. Soluble guanylate cyclase: The forgotten sibling
15. Soluble guanylate cyclase
16. Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: Stimulation by YC-1. NO and CO
17. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition
18. Nitric oxide: A unique endogenous signaling molecule in vascular biology (Nobel lecture)
19. YC-1, a novel activator of platelet guanylate cyclase
20. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
21. Cyclic GMP and mechanism of vasodilation
22. Molecular mechanisms and therapeutic strategies related to nitric oxide
23. Nitric oxide: Physiology, pathophysiology, and pharmacology
24. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators
25. Discovery of some of the biological effects of nitric oxide and its role in cell signaling (Nobel lecture)
26. Nitrate tolerance in angina pectoris
27. Molecular mechanisms involved in the synergistic activation of soluble guanylate cyclase by YC-1 and nitric oxide
28. Characterization of 1H[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase
29. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody
30. NO-independent regulatory site on soluble guanylate cyclase
31. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: In vivo studies
32. Substituted pyrazole derivatives condensed with six-membered heterocyclic rings
33. NO-independent stimulators of soluble guanylate cyclase
34. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications
35. New insights on the functions of the guanylyl cyclase receptors
36. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylate cyclase
37. Inhibition of platelet adhesion to collagen by cGMP-elevating agents
38. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase
39. Homodimerization of soluble guanylyl cyclase subunits. Dimerization analysis using a glutathione S-transferase affinity tag
40. 1 subunit of soluble guanylate cyclase as the heme proximal ligand
41. Long-term depression: A learning-related type of synaptic plasticity in mammalian central nervous system